GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncimmune Holdings PLC (LSE:ONC) » Definitions » Tax Expense

Oncimmune Holdings (LSE:ONC) Tax Expense : £0.21 Mil (TTM As of Feb. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Oncimmune Holdings Tax Expense?

Oncimmune Holdings's tax expense for the months ended in Feb. 2024 was £-0.01 Mil. Its tax expense for the trailing twelve months (TTM) ended in Feb. 2024 was £0.21 Mil.


Oncimmune Holdings Tax Expense Historical Data

The historical data trend for Oncimmune Holdings's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncimmune Holdings Tax Expense Chart

Oncimmune Holdings Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 Aug23
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.54 -1.32 -1.07 -0.02 0.22

Oncimmune Holdings Semi-Annual Data
May14 Nov14 May15 Nov15 May16 Nov16 May17 Nov17 May18 Nov18 May19 Nov19 May20 Nov20 May21 Nov21 May22 Feb23 Aug23 Feb24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 0.01 0.22 -0.01

Oncimmune Holdings Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Feb. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncimmune Holdings  (LSE:ONC) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Oncimmune Holdings Tax Expense Related Terms

Thank you for viewing the detailed overview of Oncimmune Holdings's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncimmune Holdings Business Description

Traded in Other Exchanges
N/A
Address
1 Park Row, MediCity - D6 Building, Leeds, GBR, LS1 5AB
Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialization of personalized immunodiagnostics for the screening, detection, and care of cancer. The company's operating segment is ImmunoINSIGHTS.

Oncimmune Holdings Headlines

No Headlines